Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Low Thrombopoietin and Elevated Fas-L Are Independent Predictors of Immune Thrombocytopenia

Johanna E. Drabek, Nina Cooper, Felix Schell, Maximilian Hartmann, Mathias J. Rummel, Beate Luxembourg, Ulrich J. Sachs

Blood (2024) 144 (Supplement 1): 2543.

https://doi.org/10.1182/blood-2024-200082

Published: 2024

Journal Articles

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

David J Kuter, Tomas Jose Gonzalez Lopez, Karolin Trautmann-Grill, Mathias J. Rummel, Philip Young-Ill Choi, Alessandra Borchiellini, Muhlis Cem Ar, Huyen Tran, Tienan Zhu, Jae-Ho Yoon, Nichola Cooper, Thomas Stauch, Pinar Tarkun, Fabienne Le Gac, Alex Allepuz, Patrick Urban, Renxin Lin, Charlotte A. Bradbury

Blood (2024) 144 (Supplement 1): 710.

https://doi.org/10.1182/blood-2024-201418

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason Melear, Suzanne Fanning, Kathryn S. Kolibaba, Christopher M. Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 812.

https://doi.org/10.1182/blood-2021-145640

Published: 2021

Journal Articles

Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial

Heiner Zimmermann, Christian Koenecke, Martin H. Dreyling, Christiane Pott, Ulrich Dührsen, Dennis Hahn, Norbert Meidenbauer, Ingeborg A Hauser, Mathias J. Rummel, Dominik Wolf, Michael Heuser, Christian Schmidt, Peter Schlattmann, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Ralf Ulrich Trappe

Blood (2021) 138 (Supplement 1): 3555.

https://doi.org/10.1182/blood-2021-146823

Published: 2021

Journal Articles

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Axel Matzdorff, MDPhD, Mascha Binder, MD, Falk Nimmerjahn, PhD, Oliver Meyer, MD PhD, Mathias J. Rummel, MD PhD, Tamara Tesanovic, PhD, Tanja Sauer

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134318

Published: 2020

Journal Articles

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Morton Coleman, MD FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134363

Published: 2020

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, MD, David Jacob Andorsky, MD, Morton Coleman, MD FACP, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134193

Published: 2020

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Amelie Boquoi, MD, Aristoteles Giagounidis, Hartmut Goldschmidt, MD, Michael Heinsch, MD, Mathias J Rummel, MD PhD, Nicolaus Kroeger, David Lopez y Niedenhoff, MD, C. Matthias Wilk, MD, Ingrida Savickaite, MD, Elias K Mai, MD, Carlo Aul, MD, Judith Strapatsas, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Rainer Haas, MD, Guido Kobbe, Roland Fenk, MD PhD

Blood (2018) 132 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2018-99-110977

Published: 2018

Journal Articles

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Guido Kobbe, Sabrina Pechtel, Fabian Zohren, MD PhD, Jürgen Barth, Alexander Christoph Burchardt, MD, Christian Buske, MD, Ariane Dienst, MD, Ulrich Germing, MD, Richard Greil, MD, Bernd Hertenstein, MD, Frank Kauff, Michael Koenigsmann, MD, Christian Lerchenmüller, MD, Thomas Michael Schroeder, MD PhD, Rainer Haas, MD, Mathias J Rummel, MD PhD

Blood (2018) 132 (Supplement 1): 4149.

https://doi.org/10.1182/blood-2018-99-118750

Published: 2018

Journal Articles

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Mathias J Rummel, MD PhD, Ann Janssens, David MacDonald, MD FRCPC, Mary-Margaret Keating, MD, Jan Zaucha, MD, Jaclyn Davis, MD, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 450.

https://doi.org/10.1182/blood-2018-99-114484

Published: 2018

Journal Articles

Anti-Glycoprotein V Autoantibodies in Patients with Immune Thrombocytopenia: Regularly Detectable and Functionally Relevant

Richard Vollenberg, MD, Rabie Jouni, Peter A. A. Norris, BSc, Monika Burg-Roderfeld, PhD, Nina Cooper, MD, Mathias J Rummel, MD PhD, Gregor Bein, MD PhD, Irene Marini, Alan H Lazarus, PhD, Tamam Bakchoul, MD PhD, Ulrich J Sachs, MD PhD

Blood (2018) 132 (Supplement 1): 1141.

https://doi.org/10.1182/blood-2018-99-118090

Published: 2018

Journal Articles

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Mathias J Rummel, Christian Buske, MD, Bernd Hertenstein, MD, Christian Lerchenmüller, MD, Michael Koenigsmann, MD, Elisabeth Lange, MD, Manfred Reeb, MD, Ulrich Kaiser, MD, Christina Balser, MD, Dirk Behringer, MD, Jan Dürig, MD, Tobias Gaska, MD, Georg Maschmeyer, MD, Georg Schliesser, MD, Alexander Christoph Burchardt, MD, Juergen Barth, Frank Kauff, Axel Hinke, PhD, Richard Greil, MD

Blood (2017) 130 (Supplement 1): 483.

https://doi.org/10.1182/blood.V130.Suppl_1.483.483

Published: 2017

Journal Articles

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Mathias J Rummel, Tae Min Kim, Franco Aversa, MD, Wolfram Brugger, MDPhD, Enrico Capochiani, Caterina Plenteda, Francesca Re, Peter Task, Christine McIntyre, Oliver Meier, Stuart Osborne, Rodney Smith, Andrew Grigg, MBBS FRACP FRCPA

Blood (2017) 130 (Supplement 1): 2834.

https://doi.org/10.1182/blood.V130.Suppl_1.2834.2834

Published: 2017

Journal Articles

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J. Rummel, Rainer Haas, Guido Kobbe

Blood (2015) 126 (12): 1407–1414.

https://doi.org/10.1182/blood-2015-03-630012

Published: 2015

Includes: Supplemental data

Journal Articles

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Blood (2014) 124 (21): 3052.

https://doi.org/10.1182/blood.V124.21.3052.3052

Published: 2014

Journal Articles

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Blood (2014) 124 (21): 4407.

https://doi.org/10.1182/blood.V124.21.4407.4407

Published: 2014

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD, Wolfram Brugger, MD

Blood (2014) 124 (21): 145.

https://doi.org/10.1182/blood.V124.21.145.145

Published: 2014

NARROW

Low Thrombopoietin and Elevated Fas-L Are Independent Predictors of Immune Thrombocytopenia

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Anti-Glycoprotein V Autoantibodies in Patients with Immune Thrombocytopenia: Regularly Detectable and Functionally Relevant

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only